ГИПОФИБРИНОЛИЗ КАК ОСНОВНОЙ ФАКТОР РИСКА ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОЛОГИЧЕСКИХ ПАЦИЕНТОВ
https://doi.org/10.18027/2224-5057-2014-3-147-154
Аннотация
Ключевые слова
Об авторах
О. Ю. Петрова
Свердловский областной онкологический диспансерг, Екатеринбург
Россия
Россия
Контактная информация: Петрова Ольга Юрьевна, ГБУЗ СО «СООД», olgapetrova@mail.ru, +79193768288
В. А. Суханов
Свердловская областная клиническая больница №1
Россия
уханов Владимир Александрович, ГБУЗ СО «СОКБ № 1», valex.s@mail.ru, +79221490722
Россия
уханов Владимир Александрович, ГБУЗ СО «СОКБ № 1», valex.s@mail.ru, +79221490722
Д. А. Левит
Свердловская областная клиническая больница №1
Россия
Россия
Левит Дмитрий Александрович, ГБУЗ СО «СОКБ № 1», lal@okb1.ru, +79222022212
Список литературы
1. Boillaud J. B. De la obliteration des veines et de son influence sur la formation des hidropisies partielles: consideration sur la hydropisies passive et general // Arch. Gen. Med. – 1823 – Vol. 1 – P. 188–204.
2. Trousseau A. Phlegmasia Alba Dolens // In.: Balliere J. B. Ed. Clinique Medicale de 1’Hotel Dieu de Paris, 2nd edition. Paris, Balliere.– 1865.– Vol. 3: – P 654–712.
3. Billroth T. Lectures on surgical pathology and therapeutics: a handbook for students and practitioners. // 8th ed. London: The New Sydenham Society – 1878. – P. 1877–8.
4. Баркаган З. С. Патогенез и терапия нарушений гемостаза у онкологических больных // Поддерживающая терапия у онкологических больных. Европейская школа по онкологии / Под ред. Личиницер М. – М.: Арго, 1996. – С. 217–224.
5. Фокин А. А., Важенин А. В. Венозный тромбоэмболический синдром у онкологических больных: диагностическое значение и меры профилактики // Третья конференция ассоциации флебологов России: Материалы. Ростов-на-Дону, 2001.– С. 186.
6. Monreal M., Fernandez-Llamazares J., Perandreu J. et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers // Thromb. Haemost. – 1997. – Vol. 78 (5). – P. 1316–1318.
7. Heit J. A., O’Fallon W.M., Petterson T. M. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study // Arch. Intern. Med. – 2002. – Vol. 162 (11). – P. 1245–1248.
8. Khorana A. A. Venous thromboembolism and prognosis in cancer // Thromb. Res. – 2010. – Vol. 125 (6). – P. 490–493.
9. Баркаган З. С. Патогенез и терапия нарушений гемостаза у онкологических больных // Поддерживающая терапия у онкологических больных. Европейская школа по онкологии / Под ред. Личиницер М. – М.: Арго, 1996. – С. 217–224.
10. Nadir Y., Hoffman R., Brenner B: Drug-related thrombosis in hematologic malignancies // Rev. Clin. Exp. Hematol. – 2004. – Vol. 8 (1). – E. 4.
11. Silverstein M. D., Heit J. A., Mohr D. N. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study // Arch. Intern. Med. – 1998. – Vol. 158. – P. 585–593.
12. Moor RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis // J. Clin. Oncol. – 2011. Vol. 29. – P. 3466–73.
13. Heit J. A., Silverstein M. D., Mohr D. N. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study // Arch. Intern. Med. – 2000. Vol. 160. – P. 809–815.
14. Levine M. N., Gent M., Hirsh J. et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer // N. Engl. J. Med. – 1988. – Vol. 318. – P. 404–407.
15. Saphner T., Tormey D. C., Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer // J. Clin. Oncol. – 1991. – Vol. 9. – P. 286–294.
16. Khorana A. A., Dalal M., Connolly G. C. et al. Incidence and Predictors of Venous Thromboembolism (VTE) Among Ambulatory High-Risk Cancer Patients Undergoing Chemotherapy in the United States // http://onlinelibrary. wiley.com/doi/10.1002/cncr.27772/pdf.
17. Swystun L. L. Modulation of hemostatic pathways by breast cancer chemotherapy agents // A Thesis for the Degree Doctor of Philosophy. McMaster University. August, 2011.
18. Khorana A. A., Francis C. W., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy // J. Thromb. Haemost. – 2007. – Vol. 5 (3). – P. 632–634.
19. S rensen H. T., Mellemkj r L., Olsen J. H. et al. Prognosis of cancers associated with venous thromboembolism // N. Engl. J. M. – 2000. Vol. 343 (25). – P. 1846–1850.
20. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Cancer-Associated Venous Thromboembolic Disease. Version 1.201.
21. McKarney L. Advances in the Treatment of Metastatic Colorectal Cancer // NE Oncology Issue – 2006 // http://www.newevidence.com/oncology/entries/ Advances_in_the_Treatment_of_Metastatic/
22. Fitch K. and Pyenson B. Cancer Patients Receiving Chemotherapy: Opportunities for Better Management // http://publications.milliman.com/research/health-rr/pdfs/ cancer-patients-receiving-chemotherapy.pdf.
23. Khorana A. A., Conolly G. C. Assessing risk of venous thromboembolism in the patients with cancer // J. Clin. Oncol. – 2009. – Vol. 27 (29). – P. 4839–4847.
24. Khorana A. A., Francis C. W., Culacova E. et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients // Cancer. – 2007. Vol. – 110. P. 2339–2346.
25. Khorana A. A., Kuderer N. M., Culacova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis // Blood. – 2008. – Vol. 111. – P. 4902–4907.
26. Heit J. A., Mohr D. N., Silverstein M. D. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study // Arch. Intern. Med. – 2000. – Vol. 160. – P 761–768.
27. Kr ger K., Weiland D., Ose C. et al. Risk factors for venous thromboembolic events in cancer patients // Ann. Oncol. – 2006. – Vol. 17. – P.297–303.
28. Mandala M, Clerici M, Corradino I, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the «SENDO experience» // Ann. Oncol. – 2012. Vol. 23. P. 1416–1421.
29. Tateo S., Mereu L., Salamano S. et al. Ovarian cancer and venous thromboembolic risk // Ginecol. Oncol. – 2005. Vol. 99. – P. 119–25.
30. Chew H. K., Wun T., Harvey D., et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers // Arch. Intern. Med. – 2006. Vol. 166 (4). – P. 458–64.
31. Khorana A. A., Francis C. W., Culacova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy // J. Thromb. Haemost. – 2007. – Vol. 5. – P. 632–4.
32. Wun T., White R. H. Epidemiology of cancer-related venous thromboembolism // Best. Pr. Res. Clin. Haematol. – 2009. Vol. 22. – P. 9–23.
33. Blom J., Doggen C. Malignancies, prothrombotic mutation, and the risk of venous thrombosis // JAMA. – 2005. – Vol. 293. – P.715–722.
34. Ahlbrecht J., Dickmann B., Ay C. et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results the Vienna Cancer and Thrombosis Study // J. Clin. Oncol. – 2012. Vol. 30. – P. 3870–5.
35. Dickmann B., Ahlbrecht J., Ay C. et al. Regional lymph node metastases are strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study // Haematologica.– 2013. Vol. 98. P. 1309–1314.
36. Surgical wound healing complications in metastatic colorectal cancer patients with bevacizumab // J. Surg. Oncol. – 2005. – Vol. 91. – P. 173–180.
37. Choueri T. K., Schutz F. A., Je Y. et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials // J. Clin. Oncol. – 2010. – Vol. 28. – P. 2280–2285.
38. Cavo M., Zamagni E, Cellini C. et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy // Blood. – 2002. – Vol. 100. – P. 2272–2273.
39. Petrelli F., Cabiddu M., Borgonovo K. et al. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials // Ann. Oncol. – 2012. Vol. 23. – P.1672–1679.
40. Pabinger I., Thaler J., Ay C. Biomarkers for prediction of venous thromboembolism in cancer // Blood. – 2013. – Vol. 122. – P. 2011–2018.
41. Khorana A. A., McCrae K. R. Risk stratification strategies for cancer-associated thrombosis: an update // Thromb. Res. – 2014. – Vol. 133 (S2). – P 35–38.
42. Lyman G. H., Khorana A. A., Kuderer N. M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update // J. Clin. Oncol. – 2013. – Vol. 31. P. 2189–2204.
43. RUSSCO. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных // Практические рекомендации.– Версия 2013.– С.372–376.
44. Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients // Blood. – 2010.– Vol. 116.– P. 5377–5382.
45. K nigsbr gge O., Pabinger I., Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS) // Thromb. Res. – 2014. – Vol. 133 (S2). – P. 39–43.
46. Verso M., Agnelli G., Barni S. et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score // Intern. Emerg. Med. – 2012. – Vol. 7. – P. 291–292.
47. translate.academic.ru
48. Шилова Ю. Н., Шилова А. Н., Кармадонова Н. А. и др. Изменение показателей коагуляционного гемостаза у онкологических больных // Сибирский онкологический журнал. – 2013. – Приложение 1.
49. Sun N. C., McAfee W.M., Hum G. J. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies // Am. J. Clin. Pathol. – 1979. – Vol. 7. – P. 10–6.
50. Nand S, Fisher SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications // J. Clin. Oncol. – 1987. – Vol. 5. – P. 1998–2003.
51. Buccheri G., Ferrigno D., Ginardi C. et al. Haemostatic abnormalities in lung cancer: prognostic implications // Eur. J. Cancer. – 1997. – Vol. 33. – P. 50–55.
52. Johnson M.J, Walker I. D., Sproule M. W. et al. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer // Clin. Lab. Haematol. – 1999. – Vol. 21. – P. 51–54.
53. Sallah S., Wan J. Y., Nguyen N. P. et al. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study // Thromb. Haemost. – 2001. – Vol. 86. – P. 828–233.
54. Sallah S, Husain A, Sigounas V et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy // Clin. Cancer. Res. – 2004. – Vol. 10. – P. 7238–7243.
55. Miller G. J., Bauer K. A., Howarth D. J. et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway // J. Thromb. Haemost. – 2004. – Vol 2. – P. 2107–2114.
56. Суханов В. А. и др. Принципы мониторинга системы гемостаза и медикаментозной коррекции свертывания крови у реанимационных больных // Интенсивная терапия. – 2009. – 3 (17) – C. 176–178.
57. Haas C. E. Monitoring Anticoagulation Therapy in the Critically Ill // The Society of Critical Care Medicine (SCCM). – April 2008.
58. Суханов В. А., Петрова О.Ю, Левит А. Л. Значение клинической гемостазиологии в интенсивной терапии // Интенсивная терапия и анестезия. – 2014. – № .1 (6). – С. 43–46.
59. Moore H. B., Moore E. E., Gonzalez E. et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: The spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy // J. Trauma Acute Care. Surg. – 2014. – Vol. 21. – Epub ahead of print.
60. Sukhanov V. A., Petrova O. Y. Application of thromboelastography parameters for the prediction of venous thromboembolism in cancer patients receiving chemotherapy // Thromb. Res.– 2014.– Vol. 133 (S2).– S 203.
61. Rickles F. R., Falanga A. Activation of clotting factors in cancer // Cancer Treat. Res. – 2009. – Vol. 148. – P. 31–41.
62. Falanga A., Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer // Hamostaseologie. – 2012. – Vol. 32. – P. 115–125.
63. Falanga A., Tartari C.J,. Marchetti M.. Microparticles in tumor progression // Thromb. Res. – 2012. – Vol. 129 (Suppl. 1). – S132–6.
64. Наместников Ю. А. Диагностика гиперкоагуляции с помощью теста генерации тромбина // Автореферат диссертации на соискание ученой степени кандидата медицинских наук. – Санкт-Петербург. Февраль 2012 г.
65. Guyatt G. H., Akl E. A., Crowther M. et al. Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis. – 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines // Chest. – 2012. – 141. – 7S-47S.
66. Kinasewitz G. Coagulopathy of the critically ill // XXIV ISTH Congress. Amsterdam, June 29 – July 4, 2013.
67. Johansson P. I., S rensen A.M et al. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study // Critical Care. – 2011. – Vol. 15. – R272 http://ccforum.com/content/15/6/R272.
68. Marchal G., Leroux M. E., Samama M. – Atlas de Thrombodynamographie: Editeur SPEI. Paris, 1960.
69. Spalding GJ, Hartrumpf M, Sierig T, et al. Cost reduction of perioperative coagulation management in cardiac surgery: value of bedside thrombelastography (ROTEM) // Eur J Cardiothorac Surg. – 2007. – Vol. 31. – P. 1052–1057.
70. Bowbrick V. A., Mikhailidis D. P., Stansby G. Value of Thromboelastography in the Assessment of Platelet Function // Clin. Appl. Thromb. Hemos. – 2003.– Vol. 2. – P. 137–142.
71. Hartet H. Blutgerinnungstdien mit der Thromboelastograhie, einem neun Untersuchingsverfahen // Klin Wochenscr. – 1948. – Vol. 26. – P. 577–583.
72. Hunt and B.J., Lyons G. Thromboelastography should be available in every labour ward // Int. J. Obst. Anesth.– 2005. Vol. 14.– P. 324–327.
73. Salooja N., Perry D. J. Thrombelastography // Blood. Coagul. Fibrinolysis – 2001. – Vol. 12. – P. 327–337.
74. Kang Y. G. et al. Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation // Anesth. Analg. – 1985. – Vol. 64. – P. 888–896.
75. Wohlauer M. V., Moore E. E., Harr J. et al. A standardized technique for performing thromoelastography in rodents // SHOCK. – 2011. – Vol. 36 (5). – P. 524–526.
76. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe operative bleeding: Guidelines from the European Society of Anesthesiology // EJA.– 2013.– Vol. 30 (6).– P.270–382.
77. Schlimp C. J. Chances and problems of whole blood testing and other options to estimate functional fibrinogen and coagulopathy in practice // 22nd International Congress on Fibrinolysis and Proteolysis. Marseille, France. 6–9 July 2014. Book of abstracts. – IS13.
78. Samama S. M. Perioperative management of massive bleeding // 22nd International Congress on Fibrinolysis and Proteolysis. Marseille, France. 6–9 July 2014. Book of abstracts. – IS14.
79. Sukhanov V., Petrova O.. Fibrinolysis and osmolar GAP in critically ill patients. // 22nd International Congress on Fibrinolysis and Proteolysis. Marseille, France. 6–9 July 2014. Book of abstracts. – P. 13.
80. Gorlinger K., Dirkmann D., Solomon C. et al. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability // Br. J. Anaesth. – 2012. P. 1–9. doi:10.1093/bja/aes374 / http://bja.oxfordjournals.org/content/early/2012/10/30/bja. aes374.full.pdf+html /.
81. Tanakaa K. A., Badera S. O., Gorlingerb K. Novel approaches in management of perioperative coagulopathy // Curr. Opin. Anesthesiol. – 2014. – Vol. 27. – P. 1–9.
82. Weber C. F., Gorlinger K., Meininger D. et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. // Anesthesiology. – 2012. – Vol. 117. – P. 531–547.
83. Lee J. W., Yoo Y. C., Park H. K. et al. Fresh frozen plasma in pump priming for congenital heart surgery: evaluation of effects on postoperative coagulation profiles using a fibrinogen assay and rotational thromboelastometry // Yonsei. Med. J. – 2013. Vol. 54. – P. 752–762.
84. Dekker S. E., Viersen V. A., Duvekot A. et al. Lysis onset time as diagnostic rotational thromboelastometry parameter for fast detection of hyperfibrinolysis // Anesthesiology. – 2014. – Vol. 121 (1). – P. 89–97. doi: 10.1097/ALN.0000000000000229.
85. Ronald A. and Dunning J. Can the use of thromboelastography predict and decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery? // Interact. CardioVasc. Thorac. Surg. – 2005. Vol.4. – P.456–463; originally published online Jul 11, 2005. DOI: 10.1510/ icvts.2005.115154.
86. Gabrielli A. et al. Civetta, Taylor, and Kirby‘s Manual of Critical Care. – 2012 by LIPPINCOTT WILLIAMS & WILKINS, a WOLTERS KLUWER business.
87. Суханов В. А. и Коряков И. О. Способ определения гиперкоагуляции крови // Лабораторное дело.– 1985. – N 12.– с. 722–724.
88. Spiezia L., Campello E., Rossetto V. et al. Hypofibrinolysis in patients with venous thromboembolism and cancer // Tromb. Res. – 2010. – Vol. 125. – P166–191.
89. Перлик Э. Метод фибриновых пластинок по Аструпу и т. д. Антикоагулянты. – Медицина, Ленинградское отделение, 1965. – с.341–349.
90. Перлик Э. Эуглобулиновый метод. Антикоагулянты. – Медицина, Ленинградское отделение, 1965. – с.341.
91. Spalding G. J. et al. Cost reduction of perioperative coagulation management in cardiac surgery: value of «bedside» thrombelastography (ROTEM) // Eur. J. Cardiothorac. Surg. – 2007. – Vol. 31. P. 1052–1057.
92. Kolde H. J. Haemostasis. Physiology, Pathology, Diagnostics. – Pentapharm Ltd., Basel/Switzerland, 2ndedition. – 2004. – P. 120–126.
93. Sukhanov V. A., Bauman N. N., Levit A. L. Hyperfibrinolysis: its express diagnosis and role in the development of haemorrhagic syndrome after cardiopulmonary bypass // Cor. Vasa. – 1988. Vol. 30 (6). – P. 442–446.
94. Sukhanov V. A. and Petrova O. Y. Application of thromboelastography parameters for the prediction of venous thromboembolism in cancer patient receiving chemotherapy // Thromb. Res.– 2014.– Vol. 133 (S.2).– PS 203.
95. George D. J., Agnelli G., Fisher W. et al. Venous Thromboembolism Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO // Blood. – 2011. – ASH Annual Meeting Program and Proceedings.
96. Streiff M. B., et al // NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease. http://www.nccn. org/professionals/physician_gls/pdf/vte.pdf; 2013.
97. Mandala M., Falanga A., Roila F. Management of venous thromboembolism in cancer patients: ESMP Clinical Practice Guidelines // Ann. Oncol. – 2011. – Vol. 22. – Suppl 6: vi85–92.
98. Пат. 2015515 Российская Федерация. Способ определения гиперкоагуляции крови / Суханов В. А., Коряков И. О., Амон Е. П.; заявитель Диагностический центр, патентообладатель Суханов В. А. заявл. 10.09.1991; опубл. 30.06.1994.
99. Пат. 2015515 Российская Федерация. Способ прогнозирования и диагностики гиперфибринолиза / Суханов В. А.; заявитель и патентообладатель Суханов В. А. заявл. 27.08.2007; опубл. 20.06.2009.
Рецензия
Для цитирования:
Петрова О.Ю., Суханов В.А., Левит Д.А. ГИПОФИБРИНОЛИЗ КАК ОСНОВНОЙ ФАКТОР РИСКА ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОЛОГИЧЕСКИХ ПАЦИЕНТОВ. Злокачественные опухоли. 2014;(3):147-154. https://doi.org/10.18027/2224-5057-2014-3-147-154
For citation:
Petrova O.Yu., Sukhanov V.A., Levit D.A. Hypofibrinolysis as a major factor risk of thromboembolic events in cancer patients. Malignant tumours. 2014;(3):147-154. (In Russ.) https://doi.org/10.18027/2224-5057-2014-3-147-154
Просмотров: 1738
Послать статью по эл. почте 